Related references
Note: Only part of the references are listed.IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Paul M. Ridker et al.
LANCET (2021)
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Antonio Abbate et al.
CIRCULATION RESEARCH (2020)
Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction
Antonio Abbate et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Brendan M. Everett et al.
CIRCULATION (2019)
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
Hector Bueno et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2019)
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
Anne Kristine Anstensrud et al.
OPEN HEART (2019)
The NLRP3 inflammasome in acute myocardial infarction
Stefano Toldo et al.
NATURE REVIEWS CARDIOLOGY (2018)
Interleukin-1 blockade in cardiovascular diseases: a clinical update
Leo F. Buckley et al.
EUROPEAN HEART JOURNAL (2018)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mortality Associated With Heart Failure After Myocardial Infarction A Contemporary Community Perspective
Yariv Gerber et al.
CIRCULATION-HEART FAILURE (2016)
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction A Randomized Clinical Trial
Michelle L. O'Donoghue et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial
Michelle L. O'Donoghue et al.
AMERICAN HEART JOURNAL (2015)
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)
Karen A. Hicks et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial
Matthew A. Cavender et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2015)
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial
L. Kristin Newby et al.
LANCET (2014)
Prognostic Usefulness of Serial C-Reactive Protein Measurements in ST-Elevation Acute Myocardial Infarction
Stamatis S. Makrygiannis et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth. University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]
Antonio Abbate et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia
Kumar Dharmarajan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation
Walter J. Paulus et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Peter Libby
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Therapeutic Targets in Cardiology p38 Alpha Mitogen-Activated Protein Kinase for Ischemic Heart Disease
Eva Denise Martin et al.
CIRCULATION (2012)
Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials Integrating Past Experiences to Chart a Path Forward
Zubin J. Eapen et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis
Maysoon Elkhawad et al.
JACC-CARDIOVASCULAR IMAGING (2012)
The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure
Michael S. Marber et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases A Multiethnic Case-Control Study
Nicole Cristell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)
Antonio Abbate et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Usefulness of Serial Assessment of B-Type Natriuretic Peptide, Troponin I, and C-Reactive Protein to Predict Left Ventricular Remodeling After Acute Myocardial Infarction (from the REVE-2 Study)
Marie Fertin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Inflammatory Markers and Incident Heart Failure Risk in Older Adults The Health ABC (Health, Aging, and Body Composition) Study
Andreas Kalogeropoulos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction.
Robert W. Yeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction
A. R. Kompa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
David A. Morrow et al.
CIRCULATION (2006)
The immune response in atherosclerosis: a double-edged sword
Goran K. Hansson et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Role of p38α MAPK in cardiac apoptosis and remodeling after myocardial infarction
J Ren et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2005)
C-reactive protein levels and outcomes after statin therapy
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Stress-activated MAP kinases in cardiac remodeling and heart failure new insights from transgenic studies
BG Petrich et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2004)
Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction
HK Yip et al.
CHEST (2004)
Cardiogenic shock complicating acute myocardial infarction - Expanding the paradigm
JS Hochman
CIRCULATION (2003)
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
GL Johnson et al.
SCIENCE (2002)
Share Paper
